21 May 2019
Proton Partners International Limited
Opening of proton beam therapy unit in Northumberland
Proton Partners International Limited (the "Company", or the “Group”), the holding company of a group committed to providing innovative cancer care of the highest quality, has today announced the commencement of high energy proton beam therapy services at the Rutherford Cancer Centre North East in Bomarsund, Northumberland.
The first prospective cohort of patients at the Rutherford Cancer Centre North East are already undergoing assessment for proton beam therapy.
The Group’s oncology centres in the UK offer a comprehensive range of cancer treatments to patients including high energy proton beam therapy, radiotherapy, chemotherapy, imaging and ancillary wellbeing services.
High energy proton beam therapy is a type of radiotherapy used in cancer treatment, delivering heavily charged protons in a more targeted manner to reduce damage to peripheral tissue and organs. It can also help reduce unwelcome side effects.
Mike Moran, chief executive officer of Proton Partners International, commented: “The opening of the proton beam therapy suite at our North East centre is an exciting milestone in the development of high energy proton beam facilities in this country. Historically, the UK has lagged behind Europe and North American countries in the provision of this innovative form of cancer treatment but now a complementary mix of private and public facilities are offering patients access to the most advanced technology that can enhance patient outcomes.”
The Rutherford Cancer Centre North East has formed a partnership with Fighting All Cancers Together (FACT), a leading cancer charity in the region.
Joanne Smith, founder of FACT, said: “The arrival of high energy proton beam therapy is an exciting development for the region. Given that the North East has the highest rate of cancer incidence in England, new advances in the provision of state-of-the-art cancer care to patients in the region is very welcome. We are delighted to have partnered with the Rutherford to ensure patients receive a supportive, professional and holistic experience during a challenging time.”
The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
The directors of the Company accept responsibility for the content of this announcement.